Fair value changes

Recent Articles

RELATED ARTICLES

  1. This pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit.
    WuXi AppTec posts lower profits but avoids more share price pain  
    2359.HK 603259.SHG
  2. U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
    2269.HK 2359.HK 2268.HK
  3. Potential U.S. targeting casts shadow over WuXi AppTec family
    2359.HK 603259.SHG
  4. WuXi Bio prescribes share buyback to relieve revenue pain
    2269.HK
  5. WuXi AppTec mulls gene unit sale to soften U.S. legal blow
    2359.HK 603259.SHG
  6. FAST NEWS: JPMorgan boosts WuXi AppTec stake
    2359.HK 603259.SHG
  7. China-focused Tigermed staves off biopharma gloom
    3347.HK 300347.SHE
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva